RA Pharmaceuticals

January 12, 2017

Drug Development IPO Analysis: Over $4.2B Raised Globally in Q4 2016 Despite Continued NASDAQ Decline

[vc_row][vc_column][vc_column_text] Whilst the depression in the value and frequency of Drug Development IPOs on the NASDAQ market continued throughout the fourth quarter of 2016, a combined […]